0001209191-19-022658.txt : 20190402
0001209191-19-022658.hdr.sgml : 20190402
20190402171917
ACCESSION NUMBER: 0001209191-19-022658
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20190401
FILED AS OF DATE: 20190402
DATE AS OF CHANGE: 20190402
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Schinazi Raymond F
CENTRAL INDEX KEY: 0001397607
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38841
FILM NUMBER: 19726329
MAIL ADDRESS:
STREET 1: 1860 MONTREAL ROAD
CITY: TUCKER
STATE: GA
ZIP: 30084
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: PRECISION BIOSCIENCES INC
CENTRAL INDEX KEY: 0001357874
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 302 EAST PETTIGREW STREET
STREET 2: SUITE A-100
CITY: DURHAM
STATE: NC
ZIP: 27701
BUSINESS PHONE: 919-314-5512
MAIL ADDRESS:
STREET 1: 302 EAST PETTIGREW STREET
STREET 2: SUITE A-100
CITY: DURHAM
STATE: NC
ZIP: 27701
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2019-04-01
0
0001357874
PRECISION BIOSCIENCES INC
DTIL
0001397607
Schinazi Raymond F
C/O PRECISION BIOSCIENCES, INC.
302 E. PETTIGREW STREET, SUITE A-100
DURHAM
NC
27701
1
0
0
0
Common Stock
2019-04-01
4
C
0
36946
13.60
A
36946
I
By RFS Partners, LP
Common Stock
2019-04-01
4
C
0
56102
A
93048
I
By RFS Partners, LP
Convertible Promissory Note
13.60
2019-04-01
4
C
0
502466.00
D
Common Stock
36946
0
I
By RFS Partners, LP
Series B Preferred Stock
2019-04-01
4
C
0
119761
D
Common Stock
56102
0
I
By RFS Partners, LP
The securities reported herein are held of record by RFS Partners LP ("RFS"). RFS & Associates, LLC ("RFS & Associates") is the general partner of RFS, and the reporting person is a limited partner of RFS as well as the manager of RFS & Associates. The reporting person disclaims beneficial ownership of the securities held by RFS, except to the extent of any pecuniary interest therein.
The Series B Preferred Stock automatically converted into the common stock of Precision BioSciences, Inc. (the "Issuer") on a 2.134686-to-1 basis (after giving effect to the Issuer's previously completed reverse stock split) upon the closing of the Issuer's initial public offering (the "IPO").
On March 1, 2019, RFS acquired a convertible promissory note in the principal amount of $500,000 (the "2019 Note") from the Issuer. Effective upon the closing of the IPO on April 1, 2019, the 2019 Note, including accrued interest, converted into 36,946 shares of the Issuer's common stock at a price per share equal to $13.60, which represented 85% of the price per share in the IPO.
/s/ Abid Ansari, Attorney-in-Fact for Raymond F. Schinazi
2019-04-02